



PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE  
(MBHB Case No. 02-742-O; 400/144)

In the Application of:

McSwiggen et al.

Serial No.: 10/764,957

Filing Date: January 26, 2004

For: RNA Interference Mediated Inhibition  
Of Vascular Endothelial Growth Factor  
And Vascular Endothelial Growth Factor  
Receptor Gene Expression Using Short  
Interfering Nucleic Acid (siNA)

Examiner: GIBBS, Terra C.

Group Art Unit: 1635

Confirmation No. 9923

Commissioner of Patents  
P.O. Box 1450  
Alexandria, Virginia 22313-1450

Sir:

**TRANSMITTAL LETTER**

In regard to the above identified application:

1. We are transmitting herewith the attached papers for the above identified new patent application:

- ☒ Third Supplemental Information Disclosure Statement;
- ☒ Third Supplemental Information Disclosure Statement (IDS) PTO/SB/08B Form;
- ☒ Copies of IDS Citations for S/N 10/764,957 (Total 6 other documents; and
- ☒ Return Receipt Postcard.

2. With respect to additional fees, a check in the amount of \$180.00 is enclosed.

3. GENERAL AUTHORIZATION: Please charge any additional fees or credit overpayment to Deposit Account No. 13-2490. A duplicate copy of this sheet is enclosed.

4. CERTIFICATE OF MAILING UNDER 37 CFR § 1.8: The undersigned hereby certifies that this Transmittal Letter and the paper, as described in paragraph 1 hereinabove, are being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, PO Box 1450, Alexandria, Virginia 22313-1450 on 10/30 2006.

By :

  
Lisa M.W. Hillman  
Registration No. 43,673

McDONNELL BOEHNEN HULBERT & BERGHOFF LLP  
300 SOUTH WACKER DRIVE  
CHICAGO, ILLINOIS 60606  
TELEPHONE (312) 913-0001  
FACSIMILE: (312) 913-0002



**PATENT**

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE  
(MBHB Case No. 02-742-O; 400/144)**

<b>In the Application of:</b>	)	
	)	
<b>McSwiggen et al.</b>	)	
	)	<b>Examiner: GIBBS, Terra C.</b>
<b>Serial No.: 10/764,957</b>	)	
	)	<b>Group Art Unit: 1635</b>
<b>Filing Date: January 26, 2004</b>	)	
	)	<b>Confirmation No. 9923</b>
<b>For: RNA Interference Mediated Inhibition</b>	)	
<b>Of Vascular Endothelial Growth Factor</b>	)	
<b>And Vascular Endothelial Growth Factor</b>	)	
<b>Receptor Gene Expression Using Short</b>	)	
<b>Interfering Nucleic Acid (siNA)</b>	)	

**THIRD SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Dear Sir:

Pursuant to 37 C.F.R. Section 1.97 - 1.99, the Applicant wishes to make the following references of record in the above-identified application. This Third Supplemental Information Disclosure Statement is in compliance with the continuing duty of candor as set forth in 37 C.F.R. Section 1.56. Copies of the cited references are enclosed. These references are also listed on the enclosed PTO/SB/08B form.

In the judgment of the undersigned, portions of the listed references may be material to the Examiner's consideration of the presently pending claims. This statement is not a representation that the listed references have effective dates early enough to be "prior art" within the meaning of 35 U.S.C. Section 102 or Section 103.

11/06/2006 EAYALEW1 00000011 10764957

01 FC:1806

180.00 OP

Applicants enclose the fee of \$180.00 pursuant to 37 C.F.R. 1.17(p) for this filing. The Commissioner is hereby authorized to charge or credit Deposit Account Number 13-2490 for any under- or over-payment of fees associated with the papers transmitted herewith, or to credit any overpayment of same.

Respectfully submitted,  
**McDonnell Boehnen Hulbert & Berghoff LLP**

Date: 10/30, 2006 By: \_\_\_\_\_

  
**Lisa M.W. Hillman**  
**Registration No. 43,673**

McDonnell Boehnen Hulbert & Berghoff LLP  
300 South Wacker Drive, 32<sup>nd</sup> Floor  
Chicago, IL 60606  
Telephone: 312-913-0001  
Facsimile: 312-913-0002

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

NOV 03 2006

**THIRD SUPPLEMENTAL  
INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**  
(Use as many sheets as necessary)

**Complete if Known**

Application No.	10/764,957
Filing Date:	January 26, 2004
First Named Inventor	McSwiggen et al.
Art Unit	1635
Examiner Name	GIBBS, Terra C.
Attorney Docket Number	02-742-O (400/144)

Sheet 1 of 1

**U.S. PATENT DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code <sup>2</sup> (if known)			
	A	US-5,916,763	06-1999	Williams et al.	
	B	US-6,710,174	03-23-2004	Bennett et al.	
	C	US-2003/0186920	10-2003	Sirois, Martin G.	
	D	US-2003/0216335	11-2003	Lockridge et al.	
	E	US-2004/0018176	01-2004	Tolentino et al.	

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Include name of author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>
	1	Caplen, Nathan, "RNAi as a gene therapy approach," <i>Expert Opin. Biol. Ther.</i> 3(4):575-586 (2003)	
	2	Hammond, et al., "Post-transcriptional Gene Silencing by Double-Stranded RNA," <i>Nature Reviews</i> , 2:110-119 (2001)	
	3	Mahato et al., "Modulation of gene expression by antisense and antigene oligodeoxynucleotides and small interfering RNA," <i>Expert Opin. Drug Deliv.</i> , 2(1):3-28 (2005)	
	4	Scherer et al., "Approaches for the sequence-specific knockdown of mRNA," <i>Nature Biotechnology</i> , 21:12, 1457-1465 (2003)	
	5	Vickers et al., "Efficient Reduction of Target RNAs by Small Interfering RNA and RNase H-dependent Antisense Agents," <i>The Journal of Biological Chemistry</i> , 278:9, 7108-7118 (2003)	
	6	Zhang et al., "Targeted Gene Silencing by Small Interfering RNA-based Knock-Down Technology," <i>Current Pharmaceutical Biotechnology</i> , 5, 1-7 (2004)	

Examiner  
SignatureDate  
Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of U.S. Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.